Virus-like particles expressing microneme-associated antigen of Plasmodium berghei confer better protection than those expressing apical membrane antigen 1
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Malaria is a global disease affecting a large portion of the world’s population. Although vaccines have recently become available, their efficacies are suboptimal. We generated virus-like particles (VLPs) that expressed either apical membrane antigen 1 (AMA1) or microneme-associated antigen (MIC) of Plasmodium berghei and compared their efficacy in BALB/c mice. We found that immune sera acquired from AMA1 VLP- or MIC VLP-immunized mice specifically interacted with the antigen of choice and the whole P. berghei lysate antigen, indicating that the antibodies were highly parasite-specific. Both VLP vaccines significantly enhanced germinal center B cell frequencies in the inguinal lymph nodes of mice compared with the control, but only the mice that received MIC VLPs showed significantly enhanced CD4+ T cell responses in the blood following P. berghei challenge infection. AMA1 and MIC VLPs significantly suppressed TNF-α and interleukin-10 production but had a negligible effect on interferon-γ. Both VLPs prevented excessive parasitemia buildup in immunized mice, although parasite burden reduction induced by MIC VLPs was slightly more effective than that induced by AMA1. Both VLPs were equally effective at preventing body weight loss. Our findings demonstrated that the MIC VLP was an effective inducer of protection against murine experimental malaria and should be the focus of further development.
Abstract
Malaria is a global disease affecting a large portion of the world’s population. Although vaccines have recently become available, their efficacies are suboptimal. We generated virus-like particles (VLPs) that expressed either apical membrane antigen 1 (AMA1) or microneme-associated antigen (MIC) of Plasmodium berghei and compared their efficacy in BALB/c mice. We found that immune sera acquired from AMA1 VLP- or MIC VLP-immunized mice specifically interacted with the antigen of choice and the whole P. berghei lysate antigen, indicating that the antibodies were highly parasite-specific. Both VLP vaccines significantly enhanced germinal center B cell frequencies in the inguinal lymph nodes of mice compared with the control, but only the mice that received MIC VLPs showed significantly enhanced CD4+ T cell responses in the blood following P. berghei challenge infection. AMA1 and MIC VLPs significantly suppressed TNF-α and interleukin-10 production but had a negligible effect on interferon-γ. Both VLPs prevented excessive parasitemia buildup in immunized mice, although parasite burden reduction induced by MIC VLPs was slightly more effective than that induced by AMA1. Both VLPs were equally effective at preventing body weight loss. Our findings demonstrated that the MIC VLP was an effective inducer of protection against murine experimental malaria and should be the focus of further development.
참고문헌 (39)
- Aderinto N, "A perspective on Oxford, s R21", Matrix-MTM malaria vaccine and the future of global eradication efforts, 2024, pp.23(1), 16~
- World Malaria Report 2021, "World Health Organization", World Health Organization, ~ (2021)
- Marwa K, "Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa : a systematic review and meta-analysis", PLoS One, 17(3), pp.e0264339~ (2022)[DOI]
- Panda S, "Drug resistance in malaria, tuberculosis, and HIV in South East Asia : biology, programme, and policy considerations", BMJ, 358, pp.j3545~ (2017)[DOI]
- Balikagala B, "Evidence of artemisinin-resistant malaria in Africa", N Engl J Med, 385, pp.1163~1171 (2021)[DOI]
- Chenet SM, "Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana", J Infect Dis, 213(9), pp.1472~1475 (2016)[DOI]
- Kennedy DA, "Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance", Proc Natl Acad Sci USA, 115(51), pp.12878~12886 (2018)[DOI]
- Micoli F, "The role of vaccines in combatting antimicrobial resistance", Nat Rev Microbiol, 19(5), pp.287~302 (2021)[DOI]
- Schmit N, "The public health impact and cost-effectiveness of the R21", Matrix-M malaria vaccine : a mathematical modelling study, 2024, pp.24(5), 465~475
- Hammershaimb EA, "Pre-erythrocytic malaria vaccines : RTS, S, R21, and beyond", Expert Rev Vaccines, 23, pp.49~52 (2024)[DOI]
- Laurens MB, "RTS, S", AS01 vaccine(MosquirixTM) : an overview, 2020, pp.16, 480~489
- Datoo MS, "Safety and efficacy of malaria vaccine candidate R21", Matrix-M in African children : a multicentre, double-blind, randomised, phase 3 trial, 2024, pp.403, 533~544
- Schneider CG, "Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection", Vaccine, 40(31), pp.4270~4280 (2022)[DOI]
- Yao G, "A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmissionblocking antibody response against Plasmodium berghei", Parasit Vectors, 16(1), pp.403~ (2023)[DOI]
- Tottey S, "Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate", Vaccine, 41(4), pp.938~944 (2023)[DOI]
- Saveria T, "Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice", NPJ Vaccines, 7(1), pp.113~ (2022)[DOI]
- Lee SH, "Virus-like particles expressing Plasmodium berghei MSP-8 induce protection against P. berghei infection", Parasite Immunol, 42(11), pp.e12781~ (2020)[DOI]
- Harmsen C, "Immunization with virus-like particles conjugated to CIDRα1 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies", Malar J, 19(1), pp.132~ (2020)[DOI]
- Kim MJ, "Influenza virus-like particle vaccine containing both apical membrane antigen 1 and microneme-associated antigen proteins of Plasmodium berghei confers protection in mice", BMC Immunol, 23(1), pp.21~ (2022)[DOI]
- Lee DH, "Protection induced by malaria virus-like particles containing codonoptimized AMA-1 of Plasmodium berghei", Malar J, 18(1), pp.394~ (2019)[DOI]
- Chu KB, "Immune correlates of resistance to Trichinella spiralis reinfection in mice", Parasites Hosts Dis, 54(5), pp.637~643 (2016)[DOI]
- Lee SH, "Protective immunity induced by virus-like particle containing merozoite surface protein 9 of Plasmodium berghei", Vaccines(Basel), 8(3), pp.428~ (2020)[DOI]
- Treeck M, "Functional analysis of the leading malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the invasion process", PLoS Pathog, 5(3), pp.e1000322~ (2009)[DOI]
- Lal K, "Characterisation of Plasmodium invasive organelles; an ookinete microneme proteome", Proteomics, 9(5), pp.1142~1151 (2009)[DOI]
- Dutta S, "Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum", Infect Immun, 73(4), pp.2116~2122 (2005)[DOI]
- Yoshida S, "Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1-and apical membrane antigen 1-based vaccines", PLoS One, 5(10), pp.e13727~ (2010)[DOI]
- Kim MJ, "Recombinant vaccinia virus expressing Plasmodium berghei apical membrane antigen 1 or microneme protein enhances protection against P. berghei infection in mice", Trop Med Infect Dis, 7(11), pp.350~ (2022)[DOI]
- Freitas do Rosário AP, "Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody", J Immunol, 181(12), pp.8344~8355 (2008)[DOI]
- da Silva HB, "IFN-γ-induced priming maintains long-term strain-transcending immunity against blood-stage Plasmodium chabaudi malaria", J Immunol, 191(10), pp.5160~5169 (2013)[DOI]
- Prakash D, "Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India", J Infect Dis, 194(2), pp.198~207 (2006)[DOI]
- Niikura M, "IL-10plays a crucial role for the protection of experimental cerebral malaria by co-infection with non-lethal malaria parasites", Int J Parasitol, 40(1), pp.101~108 (2010)[DOI]
- Kossodo S, "Interleukin-10 modulates susceptibility in experimental cerebral malaria", Immunology, 91(4), pp.536~540 (1997)[DOI]
- Lyke KE, "Serum levels of the proinflammatory cytokines interleukin-1 beta(IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL 12(p70)in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls", Infect Immun, 72(10), pp.5630~5637 (2004)[DOI]
- Sobota RS, "Serologic and cytokine profiles of children with concurrent cerebral malaria and severe malarial anemia are distinct from other subtypes of severe malaria", Am J Trop Med Hyg, 107(2), pp.315~319 (2022)[DOI]
- Weidanz WP, "Plasmodium chabaudi adami : use of the B-cell-deficient mouse to define possible mechanisms modulating parasitemia of chronic malaria", Exp Parasitol, 111(2), pp.97~104 (2005)[DOI]
- de Roquetaillade C, "Cytokine profiles in adults with imported malaria", Sci Rep, 13(1), pp.10347~ (2023)[DOI]
- Ding Y, "Establishment of a murine model of cerebral malaria in KunMing mice infected with Plasmodium berghei ANKA", Parasitology, 143(12), pp.1672~1680 (2016)[DOI]
- Zafar I, "Babesia microti alleviates disease manifestations caused by Plasmodium berghei ANKA in murine co-infection model of complicated malaria", Front Cell Infect Microbiol, 13, pp.1226088~ (2023)[DOI]
- Fitri LE, "Bifidobacterium longum administration diminishes parasitemia and inflammation during Plasmodium berghei infection in mice", J Inflamm Res, 16, pp.1393~1404 (2023)[DOI]